Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Research & Development (2023 - 2025)

Immunome's Research & Development history spans 3 years, with the latest figure at $50.8 million for Q4 2025.

  • For Q4 2025, Research & Development rose 6.01% year-over-year to $50.8 million; the TTM value through Dec 2025 reached $177.3 million, up 36.86%, while the annual FY2025 figure was $177.3 million, 36.86% up from the prior year.
  • Research & Development reached $50.8 million in Q4 2025 per IMNM's latest filing, up from $49.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $50.8 million in Q4 2025 to a low of $3.8 million in Q3 2023.
  • Average Research & Development over 3 years is $27.5 million, with a median of $33.0 million recorded in 2024.
  • Peak YoY movement for Research & Development: soared 873.06% in 2024, then grew 6.01% in 2025.
  • A 3-year view of Research & Development shows it stood at $9.6 million in 2023, then skyrocketed by 396.94% to $47.9 million in 2024, then increased by 6.01% to $50.8 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Research & Development are $50.8 million (Q4 2025), $49.2 million (Q3 2025), and $40.5 million (Q2 2025).